ArticleScientific reports2019
A Pilot Proof-Of-Principle Analysis Demonstrating Dielectrophoresis (DEP) as a Glioblastoma Biomarker Platform.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Emerging Frontiers in acute kidney injury: The role of extracellular vesicles.Bioactive materials · 2025Review
- Unlocking the therapeutic potential of tumor-derived EVs in ischemia-reperfusion: a breakthrough perspective from glioma and stroke.Journal of neuroinflammation · 2025Review
- Design and Fabrication of Microelectrodes for Dielectrophoresis and Electroosmosis in Microsystems for Bio-Applications.Micromachines · 2025Review
- The role and application of small extracellular vesicles in glioma.Cancer cell international · 2024Review
- Early differentiation of mesenchymal stem cells is reflected in their dielectrophoretic behavior.Scientific reports · 2024Article
- Extracellular vesicles as tools and targets in therapy for diseases.Signal transduction and targeted therapy · 2024Review
- Development of a blood-based extracellular vesicle classifier for detection of early-stage pancreatic ductal adenocarcinoma.Communications medicine · 2023Article
- Extracellular-Vesicle-Based Cancer Panels Diagnose Glioblastomas with High Sensitivity and Specificity.Cancers · 2023Article
- Advances in extracellular vesicle isolation methods: a path towards cell-type specific EV isolation.Extracellular vesicles and circulating nucleic acids · 2023Review
- Decoding vesicle-based precision oncology in gliomas.Neuro-oncology advances · 2022Article
- Liquid biopsy-from bench to bedside.Neuro-oncology advances · 2022Article
- CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.Nature communications · 2022Article
- GlioMarker: An integrated database for knowledge exploration of diagnostic biomarkers in gliomas.Frontiers in oncology · 2022Article
- Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test.Communications medicine · 2022Article
- Fluid-Screen as a real time dielectrophoretic method for universal microbial capture.Scientific reports · 2021Article
- Small extracellular vesicles in cancer.Bioactive materials · 2021Review
- Secreted Extracellular Vesicle Molecular Cargo as a Novel Liquid Biopsy Diagnostics of Central Nervous System Diseases.International journal of molecular sciences · 2021Review
- Dielectrophoresis: Developments and applications from 2010 to 2020.Electrophoresis · 2021Review
- Extracellular Vesicles Derived From Stem Cells in Intervertebral Disc Degeneration.Frontiers in cell and developmental biology · 2021Review
- Circulatory Astrocyte and Neuronal EVs as Potential Biomarkers of Neurological Dysfunction in HIV-Infected Subjects and Alcohol/Tobacco Users.Diagnostics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Extracellular vesicles (EVs) are small, membrane-bound particles released by all cells that have emerged as an attractive biomarker platform. We study the utility of a dielectrophoretic (DEP) micro-chip device for isolation and characterization of EVs derived from plasma specimens from patients with brain tumors. EVs were isolated by DEP chip and subjected to on-chip immunofluorescence (IF) staining to determine the concentration of glial fibrillary acidic protein (GFAP) and Tau. EVs were analyzed from the plasma samples isolated from independent patient cohorts. Glioblastoma cell lines secrete EVs enriched for GFAP and Tau. These EVs can be efficiently isolated using the DEP platform. Application of DEP to clinical plasma samples afforded discrimination of plasma derived from brain tumor patients relative to those derived from patients without history of brain cancer. Sixty-five percent (11/17) of brain tumor patients showed higher EV-GFAP than the maximum observed in controls. Ninety-four percent (16/17) of tumor patients showed higher EV-Tau than the maximum observed in controls. These discrimination thresholds were applied to plasma isolated from a second, independent cohort of 15 glioblastoma patients and 8 controls. For EV-GFAP, we observed 93% sensitivity, 38% specificity, 74% PPV, 75% NPV, and AUC of 0.65; for EV-Tau, we found 67% sensitivity, 75% specificity 83% PPV, 55% NPV, and AUC of 0.71 for glioblastoma diagnosis. This proof-of-principle study provides support for DEP-IF of plasma EVs for diagnosis of glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.